Roche grabs first breast cancer immunotherapy approval

March 11, 2019

Roche’s Tecentriq is now the first immunotherapy drug approved by the FDA for the treatment of breast cancer.

Tecentriq, to be given with chemotherapy, was approved for treating advanced triple-negative breast cancer, which accounts for about 15 percent of cases.

In a trial of 900 women, those who received Tecentriq plus chemo went two months longer on average without their cancer worsening compared with those on chemo alone.

Read the press release.